Section of Gastroenterology
Professor of Medicine
Co-Director, Clinical Inflammatory Bowel Disease
Referring Physician Access Line: 1-877-DOM-2730
|BS||1986||Cornell University||Biological Sciences
|MD||1990||Mount Sinai School of Medicine||
|Residency||1993||Harvard University||Internal Medicine
|Fellowship||1996||The University of Chicago||Gastroenterology and Nutrition
Dr. Cohen’s research interests are primarily involved in two major areas of clinical gastroenterology: inflammatory bowel diseases and health care outcomes. His studies in IBD include investigations of both standard and experimental pharmacological therapies, including novel immunomodulatory agents, as well as studies analyzing quality of life and the economics involved in the diagnosis and treatment of inflammatory bowel disease. In the area of health care outcomes, Dr. Cohen is applying the principles of biostatistics, epidemiology, and other integral components of health outcomes research in hope to address some of the perplexing issues arising in the field of gastroenterology in the face of a changing health care system.
Crohn’s disease, ulcerative colitis, inflammatory bowel disease
- Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource utilization among patients with Crohn’s disease. J Clin Gastroenterol 2002;35(2):151-156.
- Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalizations in Crohn’s disease. Am J Gastoenterol 2000;95(2):524-530.
- Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95(5):1263-1276.
- Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn’s disease: 1st anniversary clinical experience. Am J Gastroenterol 2000;95(12): 3469-3477.
- Cohen RD, Stein R, Hanauer SB. Intravenous Cyclosporin in Ulcerative Colitis: A Five -Year Experience. Am J Gastroenterol 1999; 94(6):1587-1592.